Key facts
- This page summarizes Neil Kumar's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Feb 2022, 15:35.
Neil Kumar - 16 Feb 2022 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- BBIO
- Reported as of
- 16 Feb 2022
- Net transaction value
- -$27,271
- SEC form
- 4
- Accepted by SEC
- 18 Feb 2022, 15:35:29 UTC
- Prior SEC filing
- 07 Dec 2021
- Next SEC filing
- 18 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yi Ching Yau, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Neil Kumar filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 18 Feb 2022.
Change
- Previous filing in this sequence was filed on 07 Dec 2021.
- Current net transaction value: -$27,271.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,524
- Change %
- +0.16%
- Price
- Shares after
- 4,730,328
- Date
- 16 Feb 2022
- Ownership
- Direct
- Footnotes
- F1
BBIO
transaction
Common Stock
Tax liability
- Transaction value
- $27,271
- Shares
- -3,085
- Change %
- -0.07%
- Price
- $8.84
- Shares after
- 4,727,243
- Date
- 16 Feb 2022
- Ownership
- Direct
- Footnotes
- F2
BBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,612,722
- Date
- 16 Feb 2022
- Ownership
- See Footnote
- Footnotes
- F3
BBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,195,686
- Date
- 16 Feb 2022
- Ownership
- See Footnote
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,130
- Change %
- -10%
- Price
- $0.000000
- Shares after
- 46,164
- Date
- 16 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,130
- Exercise price
- Footnotes
- F1, F5
BBIO
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -2,394
- Change %
- -7.7%
- Price
- $0.000000
- Shares after
- 28,730
- Date
- 16 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,394
- Exercise price
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 7,524 shares of Common Stock underlying the Reporting Person's RSUs.
Footnote F3
The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Footnote F4
The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
Footnote F5
The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
Footnote F6
The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
SEC remarks
Title: Secretary, Treasurer and Chief Financial Officer